[Essai d'un dispositif non approuvé ou autorisé par la FDA américaine]
[Essai d'un dispositif qui n'est pas approuvé ou autorisé par la FDA américaine]
Patients will be asked to take part in this research study because they have mild-to-moderate knee osteoarthritis (OA) and were referred clinically for a procedure called Genicular Artery Embolization (GAE). Osteoarthritis is the most common form of arthritis. It occurs when the protective cartilage that cushions the ends of the bones wears down over time. The symptoms of OA include pain or aching, stiffness, decreased range of motion, and swelling. The purpose of this study is to evaluate the safety and effectiveness of GAE for the treatment of knee pain attributed to OA.
Research participants will be in this research study for about 3 years. The study includes a screening visit, GAE procedure, and six follow-up visits.
At the screening visit, a review of their medical history, demographics, and medications will be collected; physical examination will be completed; knee x-ray will be done; and two questionnaires on your knee pain will be administered. The GAE procedure will involve receiving sedation or medication to help them relax, lidocaine injected under the skin in the area of the body where catheters will be inserted into one of your arteries and then using x-ray, a catheter will be directed to the arteries supplying the lining of the knee. Then tiny microspheres will be injected into the artery to decrease the blood supply to this knee joint tissue.
The follow-up visits up to 12 months will include a focused physical examination of the treated knee, documentation of medications, and two questionnaires will be administered. The follow-up visits at year 2 and 3 will include documentation of medications and any new treatments for OA as well as completion of two questionnaires. Follow-up visits maybe conducted in clinic or remotely.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Kristie Kennedy, MA
- Numéro de téléphone: 312-695-4023
- E-mail: kristie.kennedy@northwestern.edu
Sauvegarde des contacts de l'étude
- Nom: Robert Lewandowski, MD
- Numéro de téléphone: 312-695-9121
- E-mail: r-lewandowki@northwestern.edu
Lieux d'étude
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Recrutement
- Northwestern University
-
Contact:
- Robert Lewandowski, MD
- Numéro de téléphone: 312-695-9121
- E-mail: r-lewandowski@northwestern.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Age 40-80 years
- Mild-to-moderate knee OA as determined by radiographs demonstrating Kellgren- Lawrence grade 2-3
- Self-reported pain of at least 5/10 VAS questionnaire
- Failure of conservative therapy, such as pain medications, for at least 3 months
- Patient must understand and sign the informed consent
- Patient can comply with the proposed follow-up schedule
- Patient can follow the post-operative management
Exclusion Criteria:
- History of rheumatoid arthritis
- Renal insufficiency precluding angiography (GFR < 50 mL/min)
- Irreversible coagulopathy
- Previous knee arthroplasty on the intended knee
- Existing knee joint infection
- Kellgren-Lawrence grade 1 or 4
- Severe atherosclerosis as manifest by claudication and/or diminished peripheral pulses
- Life expectancy < 6 months
- Infectious arthritis
- Allergy to iodinated contrast resulting in anaphylaxis
- Pregnant or interested in becoming pregnant three months from the date of the GAE procedure
- Involved in litigation or worker's compensation claims
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: GAE Procedure
All participants will undergo a procedure called Genicular Artery Embolization (GAE) that will be done to try to reduce the pain in their knees.
|
Genicular Artery Embolization is performed by either inserting a small catheter into the artery of the upper thigh or an artery at the wrist, and with the use of x-ray, the catheter is guided to the arteries supplying the lining of the knee.
Tiny particles are then injected through the catheter into these arteries, reducing the blood supply.
These small particles are considered a medical device called Embosphere Microspheres.
These microspheres are approved by the Food and Drug Administration (FDA) in the United States to treat hypervascular tumors; in the prostate arteries to relieve symptoms related to benign prostate hyperplasia; and to address arteriovenous malformations.
The use of Embosphere Microspheres in this study is considered experimental as it has not been approved by the FDA to reduce pain associated with knee OA.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Patient safety endpoints
Délai: Screening/baseline, 1, 3, and 6 months
|
Primary safety endpoints include: 1. Incidence and severity of adverse events (AEs). These include:
|
Screening/baseline, 1, 3, and 6 months
|
|
Objective clinical endpoints - Cone beam computed tomography
Délai: Immediately pre-and post-embolization
|
Change in enhancement on cone beam computed tomography (CT)
|
Immediately pre-and post-embolization
|
|
Objective clinical endpoints - VAS
Délai: Screening/baseline, 1, 3, 6, 12, 24 and 36 months
|
Change in Visual Analogue Scale (VAS), a measurement instrument where 0 represents the minimum value (e.g., no pain) and 100 (or 10) represents the maximum value (e.g., worst imaginable pain).
Consequently, higher scores indicate a worse outcome (more pain/severity), while lower scores indicate a better outcome
|
Screening/baseline, 1, 3, 6, 12, 24 and 36 months
|
|
Objective clinical endpoints - WOMAC
Délai: Screening/baseline, 1, 3, 6, 12, 24 and 36 months
|
Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a measurement instrument designed to evaluate pain, stiffness, and physical function in patients with hip or knee osteoarthritis.
Higher scores on the WOMAC indicate a worse outcome (greater pain, stiffness, and functional limitations).
|
Screening/baseline, 1, 3, 6, 12, 24 and 36 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Preliminary Effectiveness - WOMAC
Délai: Screening/baseline, 1, 3, 6, and 12 months
|
Secondary endpoint will be evaluated based on existing validated pain scoring systems.
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a measurement instrument designed to evaluate pain, stiffness, and physical function in patients with hip or knee osteoarthritis will be utilized.
Higher scores on the WOMAC indicate a worse outcome (greater pain, stiffness, and functional limitations).
|
Screening/baseline, 1, 3, 6, and 12 months
|
|
Preliminary Effectiveness - VAS
Délai: Screening/baseline, 1, 3, 6, and 12 months
|
Secondary endpoint will be evaluated based on existing validated pain scoring systems.
The Visual Analogue Scale (VAS), a measurement instrument where 0 represents the minimum value (e.g., no pain) and 100 (or 10) represents the maximum value (e.g., worst imaginable pain) will be utilized.
Consequently, higher scores indicate a worse outcome (more pain/severity), while lower scores indicate a better outcome.
|
Screening/baseline, 1, 3, 6, and 12 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Robert Lewandowski, MD, Northwestern University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- STU00223591
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .